Novavax plummets after Phase III failure

Novavax Inc. (NASDAQ:NVAX) sank $7.05 (85%) to $1.29 on Friday after its RSV F vaccine failed in the Phase III Resolve trial to treat respiratory syncytial virus (RSV) infection in elderly adults. Nov...